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Summary
Background Multiple congenital melanocytic naevi (CMN) is a rare mosaic RASopa-
thy, caused by postzygotic activating mutations in NRAS. Growth and hormonal
disturbances are described in germline RASopathies, but growth and hormone
status have not previously been investigated in individuals with CMN.
Objectives To explore premature thelarche, undescended testes, and a clinically
abnormal fat distribution with CMN through prospective endocrinological assess-
ment of a cohort of subjects with CMN, and a retrospective review of longitudi-
nal growth of a larger group of patients with CMN from outpatient clinics
(which included all subjects in the endocrinological assessment group).
Patients and methods Longitudinal growth in a cohort of 202 patients with single or
multiple CMN was compared with the U.K. National Child Measurement Pro-
gramme 2010. Forty-seven children had hormonal profiling including measure-
ment of circulating luteinizing hormone, follicle-stimulating hormone, thyroid
stimulating hormone, adrenocorticotrophic hormone, growth hormone, pro-
lactin, pro-opiomelanocortin, estradiol, testosterone, cortisol, thyroxine, insulin-
like growth factor-1 and leptin; 10 had oral glucose tolerance testing 25 had
dual-energy X-ray absorptiometry scans for body composition.
Results Body mass index increased markedly with age (coefficient 0119, SE 0016
standard deviation scores per year), at twice the rate of the U.K. population, due
to increased adiposity. Three per cent of girls had premature thelarche variant
and 6% of boys had persistent undescended testes. Both fat and muscle mass
were reduced in areas underlying large naevi, resulting in limb asymmetry and
abnormal truncal fat distribution. Anterior pituitary hormone profiling revealed
subtle and variable abnormalities. Oral glucose tolerance tests revealed moderate–
severe insulin insensitivity in five of 10, and impaired glucose tolerance in one.
Conclusions Interpersonal variation may reflect the mosaic nature of this disease
and patients should be considered individually. Postnatal weight gain is poten-
tially related to the underlying genetic defect; however, environmental reasons
cannot be excluded. Naevus-related reduction of fat and muscle mass suggests
local hormonal or metabolic effects on development or growth of adjacent tis-
sues, or mosaic involvement of these tissues at the genetic level. Premature the-
larche and undescended testes should be looked for, and investigated, as for any
child.
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What’s already known about this topic?
• CMN are caused by postzygotic mutations in the gene NRAS in the majority of
cases, classifying it within the group of mosaic RASopathies.
• Other germline and mosaic RASopathies are known to have growth and hormonal
abnormalities.
• No studies have been done on growth or endocrinology in children with CMN.
What does this study add?
• Average body mass index increases markedly with age compared with the normal
population; this is due to increased adiposity, and can be associated with insulin
insensitivity.
• Premature thelarche variant and persistent undescended testes are not infrequent
findings, but puberty appears to develop normally.
• Both fat and muscle mass can be reduced in areas underlying large naevi, resulting
in asymmetry.
Congenital melanocytic naevi (CMN) are moles that are pre-
sent from birth. These can be isolated cutaneous lesions, single
or multiple (defined as two or more CMN at birth), or when
multiple can be associated with extracutaneous abnormalities,
then termed CMN syndrome. Extracutaneous associations
described thus far are characteristic facial features,1 and a wide
range of neurological abnormalities detectable on magnetic
resonance imaging (MRI),2,3 seen in approximately 20% of
children with more than one CMN at birth.4 Molecular studies
have established that approximately 80% of cases of multiple
CMN or CMN syndrome are caused by mosaicism for onco-
genic mutations in codon 61 of NRAS,5 classifying the majority
as a mosaic RASopathy. Primary melanoma can arise within
the skin or central nervous system (CNS), more commonly in
those with a severe cutaneous phenotype,6 and this malignant
complication is associated with further genetic events.5
Many RASopathies manifest abnormalities of pre- or postna-
tal growth, or of endocrine dysfunction. For example, neurofi-
bromatosis type 1 is characterized by macrocephaly,7 early
puberty and growth failure,8 and Costello syndrome babies
have a higher than average birthweight9 often with hypogly-
caemia.10 Moreover, cardio–facio–cutaneous syndrome, Noo-
nan syndrome and Noonan syndrome with multiple lentigines
are associated with postnatal short stature, and complex subtle
endocrine abnormalities are seen frequently in Noonan syn-
drome.11,12 The molecular mechanisms behind such variation
in growth and endocrine abnormalities in the RASopathies is
not understood; however, the MAPK pathway is known to be
involved in metabolic signalling.13
Several clinical observations directed our attention to meta-
bolic and endocrine function in children with CMN (Fig. 1):
firstly, the clinically well-recognized decrease in bulk of sub-
cutaneous tissues under large CMN, hitherto thought to be fat
atrophy but never formally studied; secondly, the previously
undescribed presentation of premature thelarche variant in a
series of young girls with CMN; thirdly, the occurrence of
undescended testes in some babies with bathing trunk naevi
(i.e. affecting the genital area).
Premature thelarche variant (sometimes termed exaggerated
thelarche) is a relatively rare subset of premature secondary
sexual development that shares features with both isolated pre-
mature thelarche and precocious puberty.14 It is characterized
biochemically by the dominance of serum concentrations of
follicle-stimulating hormone (FSH) over luteinizing hormone
(LH), and clinically by a slight acceleration in growth, the
appearance of sparse pubic hair together with breast develop-
ment, and/or minor increases in uterine measurements,15 in
the presence of a normal MRI of the CNS. It does not affect
final height, unlike true precocious puberty.
Growth and hormone status have not previously been inves-
tigated in individuals with CMN. We recruited a cohort of
subjects with CMN for prospective endocrinological assess-
ment, and used a larger group of patients with CMN from
outpatient clinics (which included all subjects in the
endocrinological assessment group) for a retrospective review
of longitudinal growth.
Patients and methods
This study was approved by the Great Ormond Street Hospital
for Children (GOSH)/Institute of Child Health Research Ethics
Committee and R&D office, and complies with the Declaration
of Helsinki protocols.
Growth study
Patient records were obtained from 202 individuals with CMN
seen sequentially in the outpatient department of GOSH
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between December 2009 and February 2011, and all recorded
growth measurements were analysed retrospectively. Data sets
collected comprised weight, height and occipito–frontal cir-
cumference (OFC) measurements, CMN phenotype, neurolog-
ical status (clinical and radiological) and family history. CMN
phenotype was classified as in Table S1 (see Supporting Infor-
mation) as previously published.16,17 Weight and height were
measured by a paediatric nurse, and OFC was measured by a
single observer (V.K.) in more than 95% of cases. OFC at the
oldest age measured was used in all analyses to allow for any
settling of head circumference after birth. One patient was
removed from OFC analysis as there was an unrelated reason
for microcephaly (postnatal hypoglycaemic injury).
The median number of measurement sets from each patient
was 30 (range 1–14). The mean age of the children at the
time of analysis was 52 years (SEM 04). The time covered
by the study was 468 years, with 765 sets of postnatal growth
measurements obtained for 184 individuals (88 males). Birth-
weight and delivery details were available for 157 children.
Endocrine study
Patient group
All families in the growth study with children aged 1 year or
more were invited to take part in the endocrine study and 47
gave written consent to participate. The lower age limit of
1 year was to avoid any influence of maternal hormones from
pregnancy, and to allow the use of topical anaesthetic cream
for venepuncture.
Venous blood samples were obtained from 47 children (29
females, 18 males) of mean age 63 years (SEM 06) between
0930 and 1130 h, and analysed for the following concentra-
tions: pro-opiomelanocortin (POMC), adrenocorticotrophic
hormone (ACTH), thyroid stimulating hormone (TSH), LH,
FSH, growth hormone (GH), prolactin, insulin-like growth
factor 1 (IGF-1), cortisol, estradiol, testosterone and thyrox-
ine. Blood for the measurement of POMC was collected into
ethylenediamine tetraacetic acid tubes containing aprotinin
onto ice. Serum and plasma were collected by standard meth-
ods within 2 h of venepuncture, and frozen until required. All
hormones were measured in the GOSH diagnostic biochem-
istry laboratory other than POMC, which was measured using
a validated immunoassay.18
Control group
In the absence of published data on systemic plasma POMC
concentrations in children, and poorly defined reference
ranges for leptin concentrations, we recruited a control group
specifically for these measurements. We obtained written con-
sent for 19 children (10 females) having laser surgery for sin-
gle port-wine stains with no other abnormalities, and blood
samples were taken between the hours of 0900 and 1100 h,
comparable with the CMN group. The mean age of this group
was 52 years, comparable with the CMN group. Blood collec-
tion and handling was the same as for the patient group. For
all other hormone concentrations the hospital reference ranges
were used.
Oral glucose tolerance tests
Ten children with multiple CMN underwent an oral glucose
tolerance test (OGTT) following the standard hospital proto-
(a)
(d) (e)
(b) (c)
Fig 1. Clinical images of children with
multiple congenital melanocytic naevi
showing (a–c) lack of bulk of underlying
tissues associated with overlying naevus: (a)
decreased girth but not length of left leg; (b)
lower abdomen; (c) decreased girth but not
length of right arm; (d) characteristic pubic
hair development in a child of 7 years,
without other secondary sexual development;
(e) premature thelarche in a child of 1 year,
not geographically associated with naevi.
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col. Patient ages, BMI, and detailed results are shown in
Table S2 (see Supporting Information); all were postpubertal.
Briefly, the patients fasted from midnight the night before, an
intravenous cannula was inserted the following morning, and
then baseline insulin and glucose (as well as IGF-1, IGF-BP3,
inhibin, LH, FSH and vitamin D) were measured half an hour
after cannula insertion. A standard dose of glucose was then
ingested orally, and insulin and glucose measured at 30, 60
and 90 min.
Dual-energy X-ray absorptiometry scanning
A whole-body dual-energy X-ray absorptiometry (DXA) scan
to examine body composition was performed on 25 children
with CMN using Lunar Prodigy instrumentation (GE Medical
Systems, Slough, U.K.) in conjunction with software v.121.
All scans were performed by one operator (J.W.) with the
subject wearing light indoor clothing. The scan provides val-
ues for whole-body and regional (trunk and limbs) fat mass,
bone mineral content and nonosseous lean. Values were con-
verted to standard deviation score (SDS) using the LMS
method19 from reference data collected using the same instru-
ment.20 The precision of soft tissue analysis for a Lunar DPX-L
instrument (regarded by the manufacturer, GE Medical Sys-
tems, as similar to our own model) established by repeated
measurements of humans on 4 successive days was reported
as 1% for fat-free mass and 2% for fat mass.21
Statistical analysis
Growth measurements including birthweight were expressed as
SDS relative to the British 1990 growth reference, using the
LMSgrowth add-in for Excel.19,22,23 The age trend in body
mass index (BMI) SDS within individuals was modelled with
random-effects regression. For comparison the prevalence of
being overweight for years 1 and 6 in the National Child Mea-
surement Programme 2010 was obtained24 and expressed as an
annual trend in SDS. The methods of initiation of labour and of
delivery were compared with the most recently available U.K.
national statistics,25 using the chi-square test with Yates’s cor-
rection. Mean POMC and leptin levels between patient and con-
trol groups were compared by independent t-test.
Results
Birthweight, occipito–frontal circumference, delivery and
gestation results
Information on type of birth, gestation and birthweight was
available for 157 children, 149 born at full term (37–
42 weeks; 61 males) and eight born prematurely. Birthweight
distribution for full-term infants was normal, mean and med-
ian 331 kg (SD 047) for females and 355 kg (SD 044) for
males (Fig. S1; see Supporting Information). The mean birth-
weight SDS for the whole group was 002. Mean OFC SDS
was 017 (Fig. S1; see Supporting Information), and OFC was
not associated with either clinical or radiological neurological
phenotype.
Data on delivery were compared with the most recent
Hospital Episode Statistics data for the U.K. population.23,25
Labour was induced in 26% of mothers in the CMN cohort,
compared with 8% in the normal U.K. population
(P < 0001) (Fig. S1; see Supporting Information). Reasons
for induction were failure of contractions to begin, either over
41 weeks’ gestation or after spontaneous rupture of mem-
branes (55%), with maternal hypertension the next most com-
mon reason (16%).
Postnatal growth results
BMI SDS increased significantly with age (Fig. 2), at a rate of
0119 (SE 0016 SDS per year; P < 0001). The corresponding
National Child Measurement Programme rates for overweight
were 231% in year 1 (age 5–6 years) and 334% in year 6
(age 10–11 years), corresponding to an underlying BMI SDS
change from 074 to 043 over the 5 years, or 0061 SDS
per year for U.K. children as a whole,24 close to half the rate
of the CMN cohort. The BMI SDS was not associated with the
severity of cutaneous phenotype on regression analysis using
Projected Adult Size of the largest CMN, or single vs. multiple
(more than one at birth) CMN, or total number of CMN as
variables.
Comparison of endocrine study and growth cohorts
The characteristics of the growth cohort and the endocrine
study cohort subset were compared with look for bias due to
self-selection based on endocrine abnormalities or severity of
CMN phenotype. Cutaneous phenotype profiles were very sim-
Fig 2. Markedly increasing body mass index (BMI) standard deviation
score (SDS) with age in longitudinal growth measurements in the
congenital melanocytic naevi patient cohort, analysed by random-
effects regression.
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ilar in both these groups (Table S1; see Supporting Informa-
tion). In addition, there were no significant differences in
first-degree family history rates of all endocrine or thyroid dis-
ease between the two groups.
Circulating hormone levels
Several anterior pituitary hormone concentration abnormalities
were noted in the children with CMN (Table 1); most notably
LH was undetectable (< 02 U L1) in 71% of those tested.
The hospital reference ranges for LH were based on Immulite
company values, and independent establishment of the refer-
ence range in normal children describes a normal distribution
within the following ranges: male 0–13 years: < 01–40,
13–19 years: < 01–37 L1; female 0–6 years: < 01–33,
6–11 years: < 01–50, 11–15 years: < 01–134, 15–19 years:
< 01–164 L1.26 On this basis, one would expect far fewer
than 71% to be undetectable. However, it is considered more
difficult to interpret suppressed values than raised values, and
this observation requires confirmation in future studies. In
three patients with premature thelarche variant, the same pat-
tern of undetectable LH was noted, and gonadotrophin stimu-
lation testing revealed FSH dominance over LH, supporting
the observation that LH is usually low in these patients.
Cortisol, estradiol and thyroxine concentrations were nor-
mal for age in the CMN group. Isolated GH and ACTH mea-
surements cannot be interpreted because of the cyclical nature
of secretion, but these results led us to check IGF-1 concentra-
tions in those for whom sufficient sample remained. Twenty-
one children had IGF-1 concentrations measured and six were
low, although this did not correlate with low GH measure-
ments; their ages were not significantly different from the
median of the group, excluding young age as a reason for
low IGF-1. Mean leptin concentrations were not significantly
different from controls: CMN group mean 399 ng mL1 SEM
084; control group mean 302 ng mL1 SEM 084. Four
patients had POMC concentrations greater than 100 pmol L1,
considered to be the cut-off for diagnosing POMC-secreting
tumours,27,28 with none in the control group. The unusually
high concentrations did not correlate in any obvious way with
the severity of cutaneous phenotype in the patients, and the
mean concentration was not significantly different from that
of the control group (CMN group mean 296 pmol L1 SEM
44; control group mean 332 pmol L1 SEM 37). We
assume that these values may be at the extreme of the normal
range, or there is the possibility that some factor in the
patients’ plasma is interfering with the assay. Secretion of
POMC by the large number of naevus cells could also explain
the high POMC values in the four patients. In the other
patients rapid metabolism of POMC to its cleavage product a-
melanocyte-stimulating hormone (MSH) cannot be excluded.
However, despite considerable evaluation of a-MSH kits, it
was not possible to measure it reliably.
Oral glucose tolerance tests
Results for the 10 children with multiple CMN who under-
went an OGTT are shown in Fig. 3 and Table S2 (see Support-
Table 1 Abnormal circulating hormone concentrations for 47 patients in the CMN cohort, with respect to standard Children’s Hospital normal
ranges. Single ACTH and GH concentrations should be interpreted with caution due to circadian changes
TSH ACTH GH IGF-1 PL LH FSH POMC
Concentration low, n (%) 0 (0) 10 (22) 5 (11) 5 (24) 6 (14) 32 (71) 5 (11) 0 (0)
Concentration high, n (%) 2 (4) 1 (2) 15 (33) 0 (0) 2 (5) 2 (4) 3 (6) 4 (9)
Missing 2 1 1 26 3 2 2 0
CMN, congenital melanocytic naevi; TSH, thyroid stimulating hormone; ACTH, adrenocorticotrophic hormone; GH, growth hormone; IGF-
1, insulin-like growth factor 1; PL, prolactin; LH, luteinizing hormone; FSH, follicle-stimulating hormone; POMC, pro-opiomelanocortin.
(a)
(b)
Fig 3. Graphic illustration of change in concentrations of circulating
blood (a) glucose and (b) insulin in 10 children with multiple
congenital melanocytic naevi, after ingestion of a standardized oral
glucose dose. Each coloured line represents a different patient. Raw
data is shown in Table S2 (see Supporting Information).
© 2015 The Authors. British Journal of Dermatology
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ing Information). Fasting glucose and insulin were within
normal limits; however, five of the 10 children demonstrated
moderate–severe insulin insensitivity, and one was suggestive
of impaired glucose tolerance.
Dual-energy X-ray absorptiometry
Results for the 25 children with multiple CMN who under-
went DXA scanning are shown in Fig. 4 and Table S3 (see
Supporting Information). Two important conclusions could
be drawn: firstly, that in children with increased BMI this
increase was attributable to increased adiposity rather than
overgrowth of other tissues such as muscle or bone; sec-
ondly, not only fat but muscle was reduced underlying large
CMN, but no evidence for bony underdevelopment was
seen.
Premature thelarche, undescended testes and early pubic
hair growth
On review of our GOSH CMN registry at the time of the col-
lection of hormone levels, at a point when detailed face-to-
face phenotyping data were available for 224 (101 male) chil-
dren, 3% of girls with any size of CMN had premature the-
larche variant and 6% of boys had at least one undescended
testis persistent at the age of 1 year (four unilateral, one bilat-
eral), all of which required surgical correction. Among the
girls, none of the largest CMN overlay the breast tissue, and
of the boys four had their largest CMN in a bathing trunk dis-
tribution but not necessarily including the genital area, and
the fifth had the largest CMN covering almost the whole of
one leg. Neither premature thelarche variant nor undescended
testes was significantly associated with the Projected Adult Size
of the largest CMN or with single vs. multiple naevi, or the
total number of CMN on logistic regression analysis; however,
the numbers involved here are small.
The incidence of unilateral undescended testis persisting to
the age of 1 year in the normal population is 1%, but is far
commoner in some RASopathies such as Noonan syn-
drome.29,30 Interestingly, the incidence of isolated premature
thelarche is associated with increasing BMI, being less than
3% at 8 years of age in those with a normal BMI but signifi-
cantly higher in those with a BMI greater than the 85th cen-
tile,31 which may be relevant to our population. However,
premature thelarche variant is much rarer, suggesting that the
subtle circulating hormonal abnormalities may also have a role
to play in individuals with CMN.
Another clinical feature is the very common development
of pubic hair at an early age in children where the CMN
involves the genital area (Fig. 1d). CMN tissue frequently
demonstrates increased hair growth, and therefore this may
simply be an exacerbation of the normal hair growth pattern
of this lesion, but in an area that is locally primed to be
androgen-responsive. This hypothesis would be supported by
the absence of any other secondary sexual characteristics in
these children at that point.
Discussion
This study describes metabolic and hormonal disturbances in
children with CMN, namely a marked increase in average
postnatal growth rate, variable subtle hormonal changes occa-
sionally accompanied by premature thelarche variant with
slow progression to puberty or persistent undescended testes,
Fig 4. DXA scanning of asymmetric limbs in
three patients to quantify asymmetry using
SDS derived from a large in-house control
population of normal children,20 showing
reduction in both fat mass and fat-free mass
(muscle) on the side affected by the naevi
(see details in the table). Osseous mass was
not reduced. Clinical and DXA images of the
one of the patients are shown. CMN,
congenital melanocytic naevi; DXA, dual-
energy X-ray absorptiometry; SDS, standard
deviation scores.
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underdevelopment of fat and muscle underlying large CMN,
and a tendency to insulin insensitivity.
Prenatal growth of children with CMN does not appear to
be affected by NRAS mosaicism, at least as measured by the
indices of birthweight and head circumference, echoing the
findings in one previous small study.32 Interestingly, in 1981
Castilla et al. reported an increase in birthweight in postmature
infants in a large series of children with CMN.33 However,
this study was conducted in the cultural context of gestation
extending naturally up to 47 weeks, and the key finding was
in fact continuing fetal weight gain after 40 weeks’ gestation,
which is against the normal pattern of weight loss after
40 weeks with a gradually failing placenta. This may be the
correlate of our unexpected finding of significantly increased
rate of induction of labour, as both factors suggest that the
complex endocrine triggers for the end of pregnancy are not
occurring. This mirrors the unexplained but consistent pattern
of delayed labour in mothers carrying babies with certain
other congenital conditions such as anencephaly.
However, looking in more detail at prenatal growth, there
is marked underdevelopment of both adipose tissue and skele-
tal muscle underlying large CMN. This does not measurably
affect limb length, while girth is clearly altered. Patients do
not usually report any symptoms relating to this feature; how-
ever, one patient consistently reports that her thinner leg is
weaker when swimming. The underdevelopment of subcuta-
neous fat and muscle is noticeable from birth, and is therefore
primarily a developmental phenomenon; however, the effect
is maintained throughout life. Surgical transplant of subcuta-
neous fat into the thinner buttock and thigh has been used to
good cosmetic effect in some of our patients. Interestingly,
and in support of this primarily being a prenatal developmen-
tal abnormality, the transplanted fat does not appear to be
affected by the naevus.
Postnatally the marked increase in BMI, which according to
DXA is due to an increase in adiposity rather than overgrowth
of muscle or bone, may be related to the psycho-social effects
of significant disfigurement leading to overfeeding or overeat-
ing, or decreased levels of physical activity. However, this is
not routinely seen with other disfiguring skin conditions in
our practice. An alternative is that it is related to the underly-
ing genetic defect, given the known metabolic effects of the
MAPK pathway,13 and known NRAS expression in adipo-
cytes,34 although there is also evidence that MAPK activation
inhibits adipogenesis.35 However, the interconnected multiple
effector pathways downstream of NRAS frequently do not
behave in predictable ways, and in a mosaic disorder with
two populations of cells with different MAPK activations this
may be even more complex. Whether NRAS is mutated in
adipocytes of patients with multiple CMN has not yet been
ascertained.
Circulating hormonal abnormalities are subtle and variable,
perhaps reflecting the mosaic nature of this condition. Patients
should therefore be considered on an individual basis, and if
presenting with premature thelarche should have a full
workup including brain imaging to exclude non-CMN-related
causes if LH/FSH are raised. Undescended testes should be
managed in the standard way. A possible mechanism underly-
ing these abnormalities could be related to overactivity of the
G-protein function of NRAS in many pathways, supported by
data from germline RASopathies,11 but further molecular work
will be required to elucidate the molecular basis.
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Supporting Information
Additional Supporting Information may be found in the online
version of this article at the publisher’s website:
Table S1. Cutaneous phenotype of the congenital melano-
cytic naevi (CMN) growth cohort (bold) and the endocrine
study cohort (not bold), showing that the two cohorts are
phenotypically similar.
Table S2. Phenotype and absolute values for 10 patients
with congenital melanocytic naevi who underwent oral glu-
cose tolerance test. All concentrations other than glucose and
insulin were measured only at baseline. 90, 930, 960 and
990 represent values at time zero, 30, 60 and 90 min,
respectively, from ingestion of standard glucose dose.
Table S3. Raw data from whole-body composition analysis
using DXA scanning of 25 patients with congenital melanocy-
tic naevi. One patient was too young for DXA SDS reference
cohort data. SDS, standard deviation score; Wt, weight; Ht,
height; DXA, dual-energy X-ray absorptiometry; BMC, bone
mineral content; FM, fat mass; FFM, fat-free mass.
Fig S1. Upper panel: histograms showing absolute birth-
weight (kg) in females and males and occipito–frontal head
circumference standard deviation score (SDS) for full-term
infants in the cohort with congenital melanocytic naevi
(CMN). Lower panel: comparison of method of onset of
labour and delivery between the CMN cohort and national
statistics 2009–10. Numbers for induction of labour do not
include elective caesarean section. P-values are for Yate’s chi-
square test.
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